Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22022205 | 0.81 | GABRA1 (0.47) | LMNAHTTTTR | |
| SCHEMBL22004402 | 0.75 | GABRA1 (0.44) | ESR1HSD17B10TSHRACLYMEN1 | |
| SCHEMBL21883610 | 0.75 | IDO1 (0.34) | ESR1HSD17B10ACLY | |
| SCHEMBL4104322 | 0.73 | TTR (0.62) | LMNAHTTESR1HSD17B10TSHR | |
| SCHEMBL22005121 | 0.72 | TTR (0.37) | TTRSLC6A3ACLYMEN1KMT2A | |
| SCHEMBL22004343 | 0.71 | ESR1 (0.46) | LMNAHTTESR1HSD17B10KDM4E | |
| SCHEMBL25466542 | 0.69 | HSD17B10 (0.44) | HSD17B10TAS1R3TAS1R1PARP10 | |
| SCHEMBL19780142 | 0.68 | GABRA1 (0.41) | LMNAHTTKDM4ETSHRTAS1R3 | |
| SCHEMBL20099495 | 0.68 | GABRA1 (0.56) | LMNAHTTTSHRSLC6A2 | |
| SCHEMBL807514 | 0.68 | LMNA (0.46) | LMNAHTTHSD17B10KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | LMNA 2463/4885HTT 4501/4885ESR1 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.